DUBLIN--(BUSINESS WIRE)--The "Wet Age - Related Macular Degeneration (Wet AMD) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
This 'Wet-Age-related Macular Degeneration (Wet-AMD) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Wet-AMD, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Wet-AMD Epidemiology
The Wet-AMD epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Study Period:
In the case of the United States, as per estimates, approximately 11 to 15 million people in the United States have AMD, and more than 1.7 million Americans have the advanced form of the disease. About 200,000 new cases of wet AMD are diagnosed each year in North America. Due to the aging population, the National Eye Institute estimates that the prevalence of advanced AMD will grow to nearly 3 million by 2020.
Wet macular degeneration accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness. This assumption was particularly used to obtain the burden of Wet-AMD among the prevalent AMD population. Age is a prominent risk factor for Age-related macular degeneration. The risk of getting advanced age-related macular degeneration increase from 2% for those ages 50-59 to nearly 30% for those over the age of 75.
A recent study by the European Eye Epidemiology (E3) Consortium collated prevalence data of 14 European population studies and reported the prevalence of any AMD among adults aged 70 years and older to be 16.2% based on the Rotterdam classification. The authors extrapolated the number of Europeans with early and late AMD and predicted almost a doubling of AMD prevalence in Europe until 2040. Yet, until today, we lack pooled European estimates on AMD incidence.
Key Findings
The total prevalent cases of Wet-AMD patients are increasing in 7MM during the study period, i.e., 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted Wet-AMD symptoms epidemiology segmented as the Total Prevalent cases of Wet-AMD, Gender-specific cases of Wet-AMD, and Age-specific cases of Wet-AMD. The report includes the prevalent scenario of Wet-AMD symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country-wise - Wet-AMD Epidemiology
- The total prevalent cases of Wet-AMD associated in 7MM countries were 4,426,968 in 2020.
- As per the estimates, the United States has the largest prevalent population of Wet-AMD.
- Among the EU5 countries, Germany had the highest prevalent cases of Wet-AMD, followed by Italy. On the other hand, Spain had the lowest prevalent cases with 300,552 cases in 2020.
Report Highlights
- 11-year Forecast of Wet-AMD epidemiology
- 7MM Coverage
- Total Diagnosed Prevalent Cases of Wet-AMD
- Prevalent Cases according to segmentation: Gender-specific cases of Wet-AMD
- Prevalent Cases according to segmentation: Age-specific cases of Wet-AMD
Key Questions Answered
- What will be the growth opportunities in the 7MM for the patient population about Wet-AMD?
- What are the key findings of the Wet-AMD epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of Wet-AMD patients across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What are the disease risk, burden, and unmet needs of the Wet-AMD?
- What are the currently available treatments for Wet-AMD?
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Key Topics Covered:
1 Key Insights
2 Executive summary
3 Organizations
4 Wet Form Age-related Macular Degeneration (Wet-AMD): Market Overview at a Glance
4.1 Total Market Share (%) Distribution of Wet Form Age-related Macular Degeneration (Wet-AMD) in 2017
4.2 Total Market Share (%) Distribution of Wet Form Age-related Macular Degeneration (Wet-AMD) in 2030
5 Wet Form Age-related Macular Degeneration (Wet-AMD): Market Overview at a Glance
5.1 Introduction
5.2 Classification and clinical manifestations
5.3 Signs and Symptoms
5.4 Risk factors
5.5 Pathophysiology
5.6 Diagnosis
5.6.1 Patients' history, clinical examination, and self-monitoring
5.6.2 Angiography
5.6.3 Optical coherence tomography (OCT)
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Assumptions and Rationale
6.3 Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM
6.4 United States
6.4.1 Total prevalent cases of Wet-AMD in the United States
6.4.2 Gender-specific cases of Wet-AMD in the United States
6.4.3 Age-specific cases of Wet-AMD in the United States
6.5 EU5 Countries
6.6 Germany
6.7 France
6.8 Italy
6.9 Spain
6.10. UK
6.11 Japan
7 KOL Views
8 Bibliography
9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/fxhnmg
